ORGO Organogenesis Holdings Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1661181 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-24.3%
TTM net income YoY-13,567.9%
TTM EPS YoY-1,400.0%
Revenue 3-yr CAGR-7.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-24.5%
Net margin-38.4%
FCF margin-0.0%
EBITDA margin-20.0%
Returns
ROE-72.2%
ROA-30.8%
ROIC (approx.)-47.0%
Asset turnover0.80x
Leverage & solvency
Liabilities / assets28.8%
Debt / equity0.00x
Current ratio3.32x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.08x
Accruals ratio-33.2%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $564.17M | $482.04M | $433.14M | $450.89M | $467.36M |
| Cost of revenue | — | $115.74M | $106.48M | $105.02M | $114.20M |
| Gross profit | — | $366.30M | $326.66M | $345.87M | $353.16M |
| R&D expense | $44.54M | $50.27M | $44.38M | $39.76M | $30.74M |
| SG&A expense | $326.24M | $294.51M | $269.75M | $283.81M | $250.20M |
| Operating income | $44.69M | -$1.28M | $12.53M | $22.30M | $72.22M |
| Interest expense | -$2.28M | $1.54M | $2.19M | $2.01M | $7.24M |
| Pretax income | $46.97M | -$2.81M | $10.39M | $20.28M | $63.09M |
| Income tax | $9.94M | -$3.67M | $5.45M | $4.75M | -$31.12M |
| Net income | $37.03M | $861,000 | $4.95M | $15.53M | $94.20M |
| EBITDA | $59.97M | $12.34M | $22.97M | $28.15M | $78.00M |
| EPS (basic) | 0.16 | -0.01 | 0.04 | 0.12 | 0.73 |
| EPS (diluted) | 0.15 | -0.01 | 0.04 | 0.12 | 0.70 |
| Weighted avg. shares (diluted) | 130.25M | 131.67M | 132.75M | 132.38M | 133.66M |
| Balance sheet | |||||
| Cash & equivalents | $93.68M | $136.15M | $104.34M | $103.29M | $114.53M |
| Receivables | $217.45M | $109.86M | $82.00M | $89.45M | $82.46M |
| Inventory | $29.63M | $26.22M | $28.25M | $24.78M | $25.02M |
| Current assets | $362.19M | $285.94M | $225.04M | $222.61M | $226.98M |
| PP&E, net | $103.71M | $89.13M | $116.23M | $102.46M | $79.16M |
| Goodwill | $28.77M | $28.77M | $28.77M | $28.77M | $28.77M |
| Intangibles | $9.14M | $12.47M | $15.87M | $20.79M | $25.67M |
| Total assets | $598.73M | $497.89M | $460.02M | $449.36M | $443.26M |
| Current liabilities | $100.12M | $77.48M | $80.51M | $75.02M | $82.70M |
| Long-term debt | — | — | $66.56M | $71.25M | $74.06M |
| Total debt | — | — | $66.56M | $71.25M | $74.06M |
| Total liabilities | $164.81M | $112.57M | $181.36M | $183.69M | $201.92M |
| Shareholders' equity | $300.13M | $262.90M | $278.66M | $265.67M | $241.34M |
| Net debt | — | — | -$37.77M | -$32.04M | -$40.47M |
| Shares outstanding | 126.95M | 125.73M | 131.32M | 130.92M | 128.68M |
| Cash flow statement | |||||
| Operating cash flow | -$10.31M | $14.21M | $30.92M | $24.86M | $61.98M |
| Capital expenditure | $14.15M | $10.03M | $24.36M | $33.90M | $31.22M |
| Free cash flow | -$24.46M | $4.18M | $6.55M | -$9.04M | $30.76M |
| Investing cash flow | -$14.15M | -$10.03M | -$24.36M | -$33.90M | -$31.22M |
| Financing cash flow | -$17.36M | $27.64M | -$5.50M | -$2.20M | -$1.04M |
| Depreciation & amortization | $15.27M | $13.62M | $10.45M | $5.84M | $5.78M |
| Stock-based compensation | $13.30M | $10.58M | $9.00M | $6.55M | $3.86M |
| Share buybacks | — | $25.48M | $0 | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.